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M ature megakaryocytes (MKs) are large multinu-cleated cells and produce many of platelets.  
Their growth is accompanied by a distinct pattern of 
nuclear division (endomitosis) [1-5].  Mitosis is regu-
lated at the molecular level in normal dividing cells.  
DNA replication in the absence of cytokinesis causes 
MKs to grow into large,  multinucleated cells,  some of 
which have DNA ploidy beyond 128N.  However,  the 
molecular mechanisms governing how DNA ploidy 
increases and how nuclear lobation occurs remain to be 
elucidated.  One general feature of myeloproliferative 
neoplasms (MPN) is increased MK counts,  but charac-
teristics such as cell size,  ploidy changes,  lobation pat-
terns,  and platelet production capacity differ among the 
MPN subtypes.  Very few studies have been performed 
to examine the associations between MK DNA content 
and hematological disease type [6].
Techniques for analyzing DNA ploidy include 
laser-scanning cytometry (LSC) and flow cytometry 
(FCM),  and the better technique to use depends on the 
aim of the analysis [7-13].  LSC is used to quantify and 
evaluate DNA content and protein localization in cells,  
and to compare these data with morphological observa-
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To investigate megakaryocyte (MK) DNA ploidy in various hematological diseases,  fluorescence microscopy 
imaging system (FMI) can be used to analyze DNA ploidy with cell morphology at the single-cell level by using 
specialized image-processing software.  Here we compared DNA ploidy obtained by FMI measured with that 
obtained flow cytometry (FCM).  With FMI,  we could evaluate the DNA ploidy in long-term preserved bone 
marrow smear samples after staining.  We next analyzed the MK DNA ploidy in 42 bone marrow smear samples 
including 26 myeloid neoplasm cases,  and we compared the DNA ploidy and platelet counts in the patients’ 
peripheral blood; the production of platelets was significantly high compared to DNA ploidy in the myelopro-
liferative neoplasms group.  The FMI method revealed that the patients with 5q- syndrome exhibited relatively 
low DNA ploidy despite high platelet counts,  and this result suggested that increased DNA ploidy is not indis-
pensable to abundant platelet production.  The FMI method for DNA ploidy will be a useful tool to clarify the 
relationship between DNA ploidy and platelet production by MKs.
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tions.  Few devices are available that are specialized for 
LSC; moreover,  the technology is complex and difficult 
to operate,  and ― in the case of dense cell populations 
― it cannot analyze DNA content in individual cells.  In 
contrast,  FCM is simple to operate and makes it easy to 
measure the DNA content of individual cells in a short 
time.  However,  it is hard to record the morphology and 
the DNA content of a given cell at the same time.  
Another technique for analyzing DNA ploidy is imaging 
flow cytometry (IFC),  a newer technology by which 
users can observe images of individual cells in combi-
nation with FCM [14 , 15].
In the present study,  we attempted to conduct a 
DNA ploidy analysis using fluorescence microscopy 
imaging (FMI),  a technique that combines fluorescent 
microscopy with specialized image-processing software.  
FMI is simple to operate and,  unlike FCM and LSC,  
FMI can quantify the DNA ploidy of individual cells.  
Using this technique,  a user can take new images after 
each round of staining to analyze DNA content at a later 
date,  and the FMI method is unaffected by specimen 
fading.  With the use of an analysis system consisting of 
fluorescent microscopy and specialized image-process-
ing software,  we evaluated the DNA ploidy of MKs in 
long-term preserved bone marrow smear samples,  and 
we compared the results obtained with the data of cyto-
logical imaging findings to search for features of MK 
ploidy in a variety of hematological diseases.
Materials and Methods
Cell lines and patient samples. A human myeloid 
cell line,  MDS-L,  was derived from a patient with 
myelodysplastic syndromes (MDS).  MDS-L cells were 
cultured in RPMI1640 medium (Gibco,  Grand Island,  
NY,  USA) supplemented with 10% fetal bovine serum 
(FBS),  2 mM L-glutamine,  and penicillin-G/strepto-
mycin.
The patient samples consisted of 42 bone marrow 
smears collected at Kawasaki Medical School Hospital 
(n = 40) and the Hiroshima University Department of 
Hematology (n = 2) from 2004 to 2013.  All bone mar-
row smears were stained by May-Grünwald-Giemsa 
(MGG) solution and long-term preserved at room tem-
perature.  The sample smears from patients: (a) who 
achieved complete remission following treatment,  or 
(b) in whom no abnormal cell infiltration was observed 
in a bone marrow examination for malignant lym-
phoma staging were assigned to the normal control 
group.  The sample smears from patients with blood 
diseases were assigned to the disease group (n = 26).  An 
overview of patients and their diseases is provided in 
Table 1.  Hematological diseases were categorized 
according to the WHO classification scheme.  Platelet 
count values were taken from the test results for the 
blood sampled at the time of the preparation of bone 
marrow smear samples (Table 1).
This study was conducted with the approval of the 
ethics committee of Kawasaki Medical School (No. 
517 , 1478).
DNA ploidy analysis by FCM. MDS-L cells were 
washed in phosphate-buffered saline (PBS) (94222-61:  
Nacalai Tesque,  Kyoto,  Japan) followed by fixation 
with 70% methanol for 20 min at 4°C.  The cells were 
then washed twice with PBS and resuspended in stain-
ing solution (10% FBS).  After being washed twice with 
PBS,  the cells were incubated with 0.1 mg/mL ribonu-
clease A (Sigma,  St Louis,  MO,  USA) for 30 min at 
37°C,  followed by DNA staining with 0.05 mg/mL 
propidium iodide (PI,  Sigma) for 20 min at room tem-
perature.  The cells were measured with a FACS Calibur 
flow cytometer (BD Bioscience,  Mansfield,  MA,  USA).  
The PI fluorescence was measured at the FL2 channel.  
Up to 10,000 events for each sample were measured by 
CellQuest software (BD Bioscience),  and DNA ploidy 
was analyzed with ModFit LTTM software (Verity 
Software House,  Topsham,  ME,  USA).
Preparation of MDS-L cells and bone marrow 
smear samples for DNA ploidy analysis by FMI.
Cytospin preparations of MDS-L cells were fixed in 4% 
formalin/50% acetone for 15 sec at room temperature,  
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Table 1　 Patient Information
Diagnosis n Age median(range)
Plt (×103/µL)
median (range)
Control 16 57.5 (13-74) 200 (38-1049)
MDS with del(5q)  4 82 (69-83) 318 (206-499)
MDS without del(5q) 10 75.5 (30-88) 78 (21-203)
CML  5 63 (48-76) 351 (202-1111)
MPN (ET＋PV)  7 70 (29-91) 867 (405-2240)
Platelet count data was only available for 3 of the MDS patients 
with 5q- syndrome.  The MPN group consisted of 3 ET and 4 PV 
patients; the 5 CML patients were not included in this group.
Plt,  platelet counts; MDS,  myelodysplastic syndromes; CML,  
chronic myeloid leukemia; MPN,  myeloproliferative neoplasms;  
ET,  essential thrombocythemia; PV,  polycythemia vera.
and washed with Tris-buffered saline (TBS) (S3001;  
Dako,  Japan).  Nuclear staining was performed with 
either 0.05 mg/mL PI (Sigma) or 0.01 mg/mL 4’,6-diami-
dino-2-phenylindole (DAPI) (Dojindo Laboratories,  
Mashiki,  Japan).  Ribonuclease A solution (final con-
centration 0.1 mg/mL) was added to the samples only 
prior to nuclear staining with PI.
Bone marrow smear samples were stained with 
MGG solution.  After MK image data ( ≥ 30 cells per 
sample) were saved in the storage system of a fluores-
cence microscope (BZ-8100; Keyence,  Osaka,  Japan) 
with the x-y coordinate mapping information,  the spec-
imens were soaked in destaining solution (acetate/
methanol) and DAPI nuclear staining was performed.  
Each MK after nuclear staining could be identified in 
the same visual fields as the MGG-stained image data 
using the x-y coordinate mapping information.
DNA ploidy analysis by FMI. We used BZ-II 
Analyzer analysis software (Keyence) to analyze the FMI 
data.  In brief,  the cells were counted in the MDS-L 
spot samples in 20 visual fields (the average cell count 
per field was 330 cells).  The nuclear DNA content is 
expressed as the luminescence integrated value (LSum),  
which was estimated by multiplying the area of the PI- 
or DAPI-stained image and the luminescence intensity 
(Fig. 1B).
The DNA content of the FMI analysis was visualized 
by plotting the LSum values of individual cells as histo-
grams.  Each representative histogram indicates the 
DNA ploidy distributions from MDS-L cells measured 
by FCM (Fig. 1A) and FMI (Fig. 1C , D).
Statistical analysis. Statistical analysis was car-
ried out using Stat Flex ver. 6 software.  All statistical 
tests were performed using two-sided,  unpaired Student’s 
t-test or the Mann-Whitney U-test.  Significance was 
defined as a p value of less than 0.05.
Results
The DNA ploidy pattern of the cell lines by the FCM 
analysis is comparable to that of the FMI analysis.
Aiming at the development of the DNA ploidy evalua-
tion of blood smear samples,  we compared the DNA 
ploidy pattern analyzed by FCM with that analyzed by 
FMI of cytospin preparations in the proliferating 
MDS-L cell line.  The MDS cell line has rarely under-
gone abnormal karyomitosis,  and as a consequence is 
allohexaploid.  A DNA ploidy distribution can be iden-
tified by defining ploidy classes based on the sequential 
doubling of DNA content from the 2N peak set on total 
nucleated cells.  For the FMI (PI),  we considered the 
value of an LSum between 32,000 and 42,000 as diploid,  
67,000-77,000 as tetraploid,  and 102,000-112, 000 as 
hexaploid (Fig. 1C).  For the FMI (DAPI),  we consid-
ered the LSum value 11,000-15,000 diploid,  23,000-
27,000 tetraploid,  and 37,000-41,000 hexaploid (Fig.1D).  
MDS-L cells were considered aneuploid if clear aneu-
ploid peaks (4N,  6N) were present.
For the FCM data,  the mean distribution ratios for 
DNA ploidy (2N: 4N: 6N) of the MDS-L cells were 
35.6 ± 1.0%: 12.3 ± 0.7%: 0.3 ± 0.1% (Fig. 1A).  For the 
FMI (PI) data,  the mean distribution ratios for DNA 
ploidy (2N: 4N: 6N) of the MDS-L cells were 
37.6 ± 4.3%: 11.5 ± 2.0%: 0.3 ± 0.3% (Fig. 1C); and for 
FMI (DAPI) data,  the corresponding data were 
37.3 ± 3.3%: 11.6 ± 1.5%: 0.4 ± 0.3% (Fig. 1D).  There 
were no significant differences in the DNA ploidy dis-
tribution ratios (2N: 4N: 6N) by nuclear stain type (PI 
vs. DAPI) or by measurement technique (FCM vs. FMI 
(PI)) (Fig. 1E).
The variations in the exposure time and the variation 
in the RBG element did not result in significant differ-
ences in DNA ploidy data in the FMI (PI) or FMI 
(DAPI) staining specimens (data not shown).
Evaluation of DNA ploidy of MKs in myeloid neo-
plasms by FMI. We measured the MK DNA ploidy 
in bone marrow smear specimens prepared from 42 
patients.  The disease group was further classified into 
myelodysplastic syndromes (MDS),  chronic myeloge-
nous leukemia (CML),  and myeloproliferative neo-
plasms (MPN).  The MDS samples were further divided 
into MDS with isolated del(5q) or 5q- syndrome and the 
other MDS cases without del(5q).  The MPN samples 
were further divided by disease subtype: essential 
thrombocythemia (ET: n = 3) and polycythemia vera 
(PV: n = 4).
The standard reference LSum value was determined 
by a selection of mature neutrophils whose ploidy was 
assumed to be 2N.  We calculated reference LSum val-
ues corresponding to DNA ploidy of 2N separately for 
each specimen by taking the mean LSum of 5-10 
mature neutrophils.  We then determined the DNA 
ploidy for each MK by dividing each cell’s LSum by the 
2N reference value and by doubling the value (Fig. 2A).
Representative examples of MKs in bone marrow 
and their DNA content are shown for various hemato-
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logical diseases in Fig. 2B.  The number inset in each 
image is the DNA content of the individual MK.  The % 
MK according to DNA ploidy in each disease is sum-
marized in Table 2 and Fig . 3A.  The MPN group 
showed a tendency to have higher DNA contents than 
the CML group,  but the difference was not significant.  
In contrast,  the MDS group showed a tendency to have 
lower MK DNA ploidy than the normal control group 
(Fig. 3A).
The platelet counts of each disease group are indi-
cated in Fig. 3B and showed significant differences 
between the normal control group and the MDS with-
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Fig. 1　 DNA ploidy distribution of the nuclear stain type (PI vs. 
DAPI) and the measurement technique (FCM vs. FMI (PI)).  A rep-
resentative immunostaining image is inset in each of the FMI pan-
els.  A,  DNA ploidy distribution based on FCM data; B,  The 
numerical conversion of the DNA contents in FMI.  LSum values are 
calculated from the luminescence intensity and nucleus area (blue 
circle); C,  DNA ploidy distribution based on FCM data following 
PI staining; D,  DNA ploidy distribution based on FCM data follow-
ing DAPI staining.  The DNA ploidy distributions are presented as 
histograms; E,  DNA ploidy distributions in MDS-L cells as deter-
mined by FCM vs. FMI.  The distribution ratios for 2N,  4N,  and 6N 
ploidy exhibited no signiﬁcant diﬀerences between the methods or 
between the nuclear stain types.
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Fig. 2　 Morphological features and DNA contents of MKs in hematological diseases.  Left-side images are May-Grünwald-Giemsa (MGG) 
stains; right-side images are DAPI nuclear stains.  A,  Circles denote mature neutrophils for the 2N reference value for integrated lumi-
nescence (LSum); an arrow indicates a megakaryocyte.  The LSum (shown as a number) is the product of the nuclear area and the ﬂuores-
cence intensity,  and is calculated separately for each cell; B,  Bone marrow MKs and their DNA ploidy are shown for various hematologi-
cal diseases.  Lower-left numbers denote DNA content (N).
out del(5q) group and between the normal control 
group and the MPN group (Fig. 3B).
To clarify the relation between the platelet counts 
and the DNA content by the disease,  the ratio of DNA 
content and the platelet counts (DNA/Plt ratio) or the 
product of DNA content and the platelet counts 
(DNA × Plt products) was calculated.  DNA/Plt ratio 
showed statistical difference between the normal con-
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Fig. 3　 Comparison of the DNA contents and platelet counts of hematological diseases.  A,  The average DNA contents of bone marrow 
MKs by hematological diseases; B,  Platelet counts in peripheral blood were compared between the diseases examined.  Values are mean 
± SD; C,  The ratio of DNA content and the platelet counts (DNA/Plt ratio); D,  The product of the DNA content and the platelet counts 
(DNA×Plt products).
Table 2　 DNA ploidy distribution of Megakaryocyte of hematological diseases
Diagnosis
% MK according to DNA ploidy DNA contents
＜4N 4-8N 8-16N 16-32N 32-64N 64-128N 128N＜ AVE
Control 0±0.8 2±3.4 15±10.9 42±13.3 33±14.3 7±6.0 2±4.2 33.5±10.0
MDS with del(5q) 6±6.8 9±7.1 29±14.8 43±19.2 14±9.9 0 0 19.6±5.3
MDS without del(5q) 4±6.7 5±8.2 22±18.9 36±13.6 27±15.9 5±6.3 0±0.9 27.0±10.7
CML 1±1.3 6±7.0 20±16.3 42±17.3 26±25.4 5±10.6 1±1.5 28.1±15.0
MPN 2±3.5 6±8.0 17±13.3 35±15.0 27±13.1 9±8.4 3±4.7 35.4±16.2
Average values of DNA contents are shown.  Values are presented as mean ±SD.
trol group and MDS with del(5q),  the normal control 
group and MPN group (Fig. 3C).  In contrast,  the 
DNA × Plt products showed a significant difference 
between the normal control group and the MDS with-
out del(5q) group and between the normal control 
group and the MPN group (Fig. 3D).
In the present study,  we focused on the ploidy of 
hypolobated MKs detected exclusively in the patients 
with MDS with isolated del(5q) or 5q- syndrome.  
Although only 4 cases of MDS with del(5q) were exam-
ined for DNA ploidy analysis,  the ploidy distribution 
was found to deviate significantly to lower the range 
from that of the normal control group (Fig. 3A).  In con-
trast,  the platelet count in the MDS with del(5q) group 
was comparable to that of the normal control group 
(Fig. 3B).
Discussion
We established a system for analyzing DNA ploidy 
by comparing cytological images with their ploidy data.  
This FMI system consists of a fluorescent microscope 
and specialized image-processing software,  and the 
specimens used in this study were preserved bone mar-
row smears after MGG staining.  Compared to the con-
ventional techniques LSC and FCM,  the FMI system 
can be easily operated and also yields favorable analyses,  
and it enabled us to successfully quantify DNA content 
and thus the DNA ploidy of normal to abnormal MKs,  
especially from the long-term preserved bone marrow 
smears of patients with a variety of hematological dis-
eases.
In general,  mature MKs have more DNA content 
with nuclear multilobation and release platelets when 
their ploidy reaches 8N or more.  The degree of nuclear 
lobation and DNA ploidy thus seem to correlate with 
each other [1 , 14 , 16].  The morphological features of 
MKs in MPN are somewhat different between the sub-
types.  For instance,  the MKs of patients with CML are 
known to be characterized by their relatively small size 
and hypolobation,  whereas the MKs of patients with ET 
are large,  polyploid,  and markedly hyperlobated,  and 
the MKs of patients with PV exhibit a phenotype inter-
mediate to those observed in CML and ET.  As these 
findings were not significant in the present study,  an 
analysis with a larger sample size is necessary to con-
firm these features of MK in MPN subtypes.  Our pres-
ent findings also support the previous reports that MKs 
in MDS patients show lower DNA ploidy compared to 
those in normal controls [17-21],  although a larger 
sample size study is necessary to examine this result.
MDS with isolated del(5q) or 5q- syndrome is dis-
criminated into the distinct MDS subtypes character-
ized by macrocytic anemia,  absent or mild leukopenia,  
normal or elevated platelet counts,  and abnormal 
hypolobated MK with eccentric nuclei [22].  It is 
important to identify the DNA ploidy of hypolobated 
MKs.  In Japan,  5q- syndrome is quite rare [23] and we 
were able to collect only 4 samples for the present study,  
but as shown in Fig. 2B and Fig. 3A,  the ploidy distribu-
tion of such MKs deviated significantly to a range that 
was lower than that of the normal control group.  This 
result might be expected from the observation of the 
bone marrow smear of the patients with 5q- syndrome,  
but to the best of our knowledge,  this study is the first 
to actually demonstrate the DNA hypoploidy of hypolo-
bated MKs.  Considering the features of 5q- syn-
drome-specific MKs that produce a large amount of 
platelets regardless of DNA hypoploidy,  it could be 
presumed that increased ploidy and nuclear lobation are 
not indispensable to abundant platelet production.
There are various mechanisms in the polyploidy for-
mation of MKs [24-27],  including a report that the 
activation and localization of aurora B by survivin and 
RhoA promote the cleavage furrow formation [28].  
However,  most of the mechanisms are still unknown.  
Further investigation of these mechanisms in conjunc-
tion with the interrelation of nuclear lobation,  DNA 
ploidy,  and platelet production is required.
Our clinical sample findings also indicate that the 
DAPI staining of cells from normal or pathological tis-
sues will be the best application for FMI.
We intend to use FMI to further measure the DNA 
ploidy of several hematopoietic cells and clarify the 
relationship between the DNA ploidy and cell dysplasia 
in bone marrow disorders.
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